Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2234389 | 0.89 | EPHX1 (0.41) | HSD17B10ALDH1A1CYP2C9HPGDALOX15 | |
| SCHEMBL3975090 | 0.80 | KMT2A (0.33) | ALDH1A1HPGDEPHX1KMT2AATM | |
| SCHEMBL2235856 | 0.79 | EPHX1 (0.38) | HSD17B10ALDH1A1CYP2C9HPGDALOX15 | |
| SCHEMBL2236322 | 0.79 | HSD17B10 (0.43) | HSD17B10ALDH1A1CYP2C9HPGDALOX15 | |
| SCHEMBL642798 | 0.73 | MTNR1A (0.43) | ALDH1A1EPHX1KMT2AATM | |
| SCHEMBL3867671 | 0.73 | EPHX1 (0.38) | HSD17B10ALDH1A1CYP2C19EPHX1KMT2A | |
| SCHEMBL11778894 | 0.72 | — | — | |
| SCHEMBL9397628 | 0.72 | ALDH1A1 (0.44) | ALDH1A1HPGDCYP2C19EPHX1KMT2A | |
| SCHEMBL15010840 | 0.72 | — | — | |
| SCHEMBL9958207 | 0.71 | THRB (0.38) | EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307239-A4 | RADIOPHARMACEUTICAL FOR DIAGNOSTIC IMAGING CONTAINING A TECHNETIUM-99M NITRIDE HETEROCOMPLEX | NIHON MEDIPHYSICS CO LTD (JP) | 2005-01-26 | — | — | EP | claimed |
| US-20040018147-A1 | Radiopharmaceutical for diagnostic imaging containing a technetium-99m nitride heterocomplex | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2004-01-29 | — | — | US | claimed |
| EP-1307239-A1 | RADIOPHARMACEUTICAL FOR DIAGNOSTIC IMAGING CONTAINING A TECHNETIUM-99M NITRIDE HETEROCOMPLEX | Nihon Medi-Physics Co., Ltd. (JP) | 2003-05-07 | — | — | EP | claimed |
| WO-2002009771-A1 | RADIOPHARMACEUTICAL FOR DIAGNOSTIC IMAGING CONTAINING A TECHNETIUM-99M NITRIDE HETEROCOMPLEX | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2002-02-07 | — | — | WO | claimed |
| US-8182789-B2 | Intermediate compound of technetium nitride complex for radiodiagnostic imaging | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2012-05-22 | — | — | US | disclosed |
| US-20100160615-A1 | INTERMEDIATE COMPOUND OF TECHNETIUM NITRIDE COMPLEX FOR RADIODIAGNOSTIC IMAGING | NIHON MED-PHYSICS CO., LTD. (JP) | 2010-06-24 | — | — | US | disclosed |
| US-7445765-B2 | Radiopharmaceutical for diagnostic imaging containing a technetium-99m nitride heterocomplex | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2008-11-04 | — | — | US | disclosed |
| EP-1307239-A4 | RADIOPHARMACEUTICAL FOR DIAGNOSTIC IMAGING CONTAINING A TECHNETIUM-99M NITRIDE HETEROCOMPLEX | NIHON MEDIPHYSICS CO LTD (JP) | 2005-01-26 | — | — | EP | disclosed |
| US-20040018147-A1 | Radiopharmaceutical for diagnostic imaging containing a technetium-99m nitride heterocomplex | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2004-01-29 | — | — | US | disclosed |
| EP-1307239-A1 | RADIOPHARMACEUTICAL FOR DIAGNOSTIC IMAGING CONTAINING A TECHNETIUM-99M NITRIDE HETEROCOMPLEX | Nihon Medi-Physics Co., Ltd. (JP) | 2003-05-07 | — | — | EP | disclosed |
| WO-2002009771-A1 | RADIOPHARMACEUTICAL FOR DIAGNOSTIC IMAGING CONTAINING A TECHNETIUM-99M NITRIDE HETEROCOMPLEX | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160615-A1 | INTERMEDIATE COMPOUND OF TECHNETIUM NITRIDE COMPLEX FOR RADIODIAGNOSTIC IMAGING | MEN1, NCDN, C1R | HSD17B10 4672/4885ALDH1A1 4466/4885CYP2C9 2896/4885 |
| US-20040018147-A1 | Radiopharmaceutical for diagnostic imaging containing a technetium-99m nitride heterocomplex | SHBG, TNNT2, TNNI3 | HSD17B10 1491/4885ALDH1A1 4698/4885CYP2C9 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.